Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
30 hedge funds and large institutions have $55.9M invested in Sorrento Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
103% more capital invested
Capital invested by funds: $27.5M → $55.9M (+$28.3M)
100% more funds holding
Funds holding: 15 → 30 (+15)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.75M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.8M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.11M |
| 4 |
B
Baird
Milwaukee,
Wisconsin
|
+$759K |
| 5 |
Jane Street
New York
|
+$734K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.83M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$356K |
| 4 |
SC
Sophrosyne Capital
New York
|
-$316K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$245K |
SRNE Hedge Fund Activity: Q1 2014 in Review
30 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2014, worth a combined $55.9M — up 103% from $27.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SRNE positions and 3 closed out — a net gain of 16 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $7.75M. The largest seller was JP Morgan Chase, cutting an estimated $1.83M.
- 30 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2014, up from 15 in Q4 2013.
- Funds reported $55.9M of Sorrento Therapeutics, Inc. stock for Q1 2014, up 103% quarter-over-quarter.
- 19 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2014 and 3 closed out, a net change of +16 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2014 was Cormorant Asset Management, an estimated $7.75M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2014 was JP Morgan Chase, an estimated $1.83M sold.
Based on aggregated 13F filings for Q1 2014.